NuFund Venture Group Invests in Papillon Therapeutics to Advance Multi-Systemic Genetic Medicines
April 15, 2024, San Diego, CA – NuFund Venture Group (‘NuFund’), California-based investment fund, is excited to declare its latest investment in Papillon Therapeutics, Inc., (‘Papillon’). Papillon stands out as a pioneering clinical-stage biotechnology company focused on multi-systemic genetic medicines for diseases characterized by neurologic, cardiac, and other tissue pathologies. This investment by NuFund represents a commitment to fostering innovation and supporting groundbreaking research in the medical field.
A UC San Diego spin-out, Papillon is advancing a pipeline of innovative treatments for life threatening conditions including Friedreich’s ataxia and Alzheimer’s disease. The company’s platform technology builds upon discoveries published by scientific co-founder, Stephanie Cherqui, Ph.D., demonstrating the therapeutic potential of gene modified hematopoietic stem and progenitor cells to durably restore function of diseased tissues throughout the body. This approach has already shown positive results in a completed Phase 1/2 clinical trial led by Dr. Cherqui.
“Our decision to invest in Papillon stems from our belief in their mission and the potential of their technology to make a significant impact on patients’ lives,” said Meredith Fidler, Ph.D., who will join the Board of Directors at Papillon. “We are thrilled to be part of this journey and to contribute to the advancement of genetic medicines.”
“NuFund has established an exciting portfolio of promising and successful biotechnology companies,” said Carter Cliff, Chief Executive Officer at Papillon. “We are grateful that they recognize the potential of our approach to develop powerful new medicines for patients who suffer from devastating diseases.”
Serhat Pala, President at NuFund Venture Group, expressed his enthusiasm for NuFund’s latest investment. “Papillon Therapeutics embodies the type of innovation and drive we look for in our investments. Their work has the potential to change the face of genetic medicines and bring hope to patients around the world,” said Pala.
About NuFund Venture Group
NuFund Venture Group represents a new wave of angel investors, pioneering a novel fund model focused on emerging technology leaders. NuFund was formerly known as Tech Coast Angels – San Diego (TCA-SD), and the organization is one of the largest, most active, and most successful early-stage investor groups over the past 20+ years. We continually strive to foster a culture that is friendly, innovative, engaging, rewarding, and fun for all stakeholders. For more information, please visit http://www.nufund.com
About Papillon Therapeutics
Papillon Therapeutics is a clinical stage biotechnology company focused on advancing multi-systemic genetic medicines. Founded by world-class leaders in cell and gene therapy, Papillon is developing a robust pipeline of potentially curative treatments for diseases with neurologic, cardiac, and other tissue pathologies. Papillon’s unique multi-systemic approach enables therapeutic protein to be delivered throughout the body and utilizes commercially proven approaches for product administration and manufacturing. For more information, please visit: https://www.papillon-tx.com/
###